Inovio Pharmaceuticals (INO) Receives Price Target

Inovio Pharmaceuticals (INO) : 4 Wall Street analysts covering Inovio Pharmaceuticals (INO) believe that the average level the stock could reach for the short term is $19.75. The maximum price target given is $31 and the minimum target for short term is around $13, hence the standard deviation is calculated at $7.8.

Inovio Pharmaceuticals (INO) : The consensus on Inovio Pharmaceuticals (INO) based on 5 analyst recommendation on the company stock is 1.4, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.


Also, Maxim Group downgrades its rating on Inovio Pharmaceuticals (NASDAQ:INO). Analysts at the Maxim Group have a current rating of Hold on the shares. The shares were previously rated Buy. The rating by the firm was issued on August 9, 2016.

Inovio Pharmaceuticals (NASDAQ:INO): The stock opened at $9.12 on Thursday but the bulls could not build on the opening and the stock topped out at $9.27 for the day. The stock traded down to $9.01 during the day, due to lack of any buying support eventually closed down at $9.14 with a loss of -0.33% for the day. The stock had closed at $9.17 on the previous day. The total traded volume was 1,007,894 shares.

Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.